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Abstract
Background:  We examine whether practices in areas with higher risks of CHD prescribe
different levels of cardiovascular drugs and describe how they differ in GP and practice
characteristics.
Methods: Propensity score matching was used to identify two groups of practices in Scotland. The
cases were in areas with 5% or more of the population in South Asian ethnic groups. The controls
were in areas with less than 1% of the population in South Asian ethnic groups and were matched
for other population characteristics.
Results: The 39 case practices have lower prescribing rates than the matched controls for all heart
disease drugs Significant different are found for six drugs (statins, ace Inhibitors, clopidogrel,
thiazides, warfarin and digoxin. The differences range from 12.8% less for amlodipine to 43.9% for
clopidogrel. The case practices also have lower prescribing costs than the unmatched group with
the exception of ace inhibitors and aspirin. The highest prescribing costs for all drugs are found in
the matched control group. The case practices are smaller than the controls, and have fewer GPs
per 1,000 patients. Case practices have fewer quality markers and receive less in total resources,
but have higher sums reimbursed to cover their employed staff costs.
Conclusion: Patients with higher risk of CHD tend to live in areas served by practices with lower
prescribing rates and poorer structural characteristics. The scale of the differences in prescribing
suggests that health care system factors rather than individual treatment decisions cause inequity
in care. Identifying whether South Asian individuals are less likely to receive heart disease drugs than
non South Asians requires individual-level prescribing data, which is currently not available in the
UK.
Background
In 2003 CHD was second only to cancer as the major
cause of mortality in Scotland. [1] Although CHD mortal-
ity has fallen in recent years death rates from CHD are
amongst the highest in the world and the second highest
in Western Europe. [2] There is a strong correlation
between increasing incidence and mortality from CHD
and deprivation. CHD is also the major cause of morbid-
ity and mortality in the South Asian population in the
United Kingdom. [3] South Asians have been found to be
at increased risk compared to the rest of the population of
England and Wales [4] by at least 40 percent. [5-7]
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Though Scotland has one of the worst incidences of heart
disease in Europe [8] only one of the 19 studies identified
in Bhopal's review was based in Scotland. [4,9]
The concept of equity is a central objective of most health
care systems in the developed world. While governments
from across the political spectrum, both in the UK and
internationally, have attempted to tackle perceived ineq-
uities in health care the concept of equity remains some-
what elusive. [10,11] A theoretical framework has been set
out which examines equity through three domains: equal
access to health care for people in equal need; equal treat-
ment for people in equal need; and equal outcomes for
people in equal need. [11] This simple framework has
been used as a basis to examine the equity of GP prescrib-
ing rates for statins and five major CHD drug groups
focused around the equal treatment in equal need
domain. [12,13] These papers are amongst a growing
body of work in the UK, which have focused on equity of
prescribing. However, these studies have largely been con-
fined to England and Wales. The purpose of this paper is
to explore the equity of prescribing for a range of heart dis-
ease drugs in Scotland. Having established prescribing dif-
ferences, the analysis then considers structural differences
in GP and practice provision. Using a matching tech-
nique, we use examine the notion of equal treatment for
people in equal need and how this relates to differences in
equal access to health care.
Many patients do not receive the appropriate treatment
for CHD. Research has found that prescribing rates of stat-
ins and lipid lowering drugs were negatively correlated
with deprivation. [9,14] The Acheson report highlighted
the need for studies of ethnic inequalities. [15] Several
studies have highlighted ethnic variations in access to and
provision of hospital interventions. [16,17] Although a
more recent study found no evidence that South Asian
ethnicity was associated with lower use of cardiac proce-
dures or drugs independent of clinical need, [18] there has
been little research conducted on the equity of prescribing
in the community.
One US study based on individual data discovered that
black and minority ethnic group patients were less likely
to be prescribed a beta-blocker. [19] There are no studies
based on individual level data from the UK. Two studies
in England have shown negative correlations between pre-
scribing of lipid-lowering drugs [14] and beta-blockers
[20] with the estimated proportion of patients from South
Asian ethnic groups. Members of ethnic minorities tend to
be situated in deprived areas and deprived areas have been
shown to have lower quality and fewer general practi-
tioner services than more affluent areas. [21-23] While a
study in Scotland has found under the new GMS contract
that achievement levels for the taking of beta blockers for
patients with CHD, was found to be negatively associated
with deprivation [24].
Since ethnicity data are not available on individual pre-
scriptions, we compare prescribing rates for practices serv-
ing areas with higher proportions of South Asian patients
to those serving areas with lower proportions of South
Asian patients. Thus, we can use higher proportions of
South Asian patients as a proxy for higher risk of CHD and
then assess whether practices with populations associated
with higher CHD prevalence have higher prescribing
rates. We use a statistical matching process since practices
differ in a range of other dimensions that may influence
prescribing. Propensity score matching is a method for
matching members of different groups based on a range of
characteristics. Comparisons of the matched groups reveal
the impact of the stratifying variable. The use of a match-
ing process allows for the formation of groups based on
their risk of having CHD, which can be assessed from their
ethnicity, deprivation, social factors such as health and
education and demographic factors. Comparisons are
made in prescribing rates of a wide range of drugs used in
the treatment of heart disease.
Methods
National data are used to give 100% coverage of practices.
Collection of characteristics of persons receiving prescrip-
tions has only recently started to be piloted in the Scottish
prescribing information system. It is therefore possible
only to analyse variations in prescribing between practices
(or higher organisational units). Ethnic compositions of
practice populations are also not collected, so these must
be estimated based on the ethnic compositions of the
areas from which practices draw their populations.
The most recent and comprehensive information on the
ethnicity of the Scottish population comes from the 2001
Census. Figures are produced for output areas (N =
42,604; average population = 117 persons) using the fol-
lowing ethnic groups: White (97.9%); Indian (0.3%);
Pakistani and Other South Asian (0.9%); Chinese (0.3%);
Other (0.6%).
We combined the Indian and Pakistani and Other South
Asian groups and calculated the proportion of each out-
put area's population from South Asian ethnic groups. We
calculated the proportion of each practice's list resident in
each output area as at September 2002 using an extract
from the Community Health Index. We attributed the
South Asian proportions to practices using this geograph-
ical breakdown to estimate the likely South Asian propor-
tion of each practice's list. This process assumes that
practices draw representative samples of individuals from
the output areas.International Journal for Equity in Health 2008, 7:18 http://www.equityhealthj.com/content/7/1/18
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We analysed the characteristics of patients and practices
that were associated with the estimated South Asian pro-
portion. We used a binomial logit multiple regression
model [25] to identify the significant population charac-
teristic predictors used to match the GP practices. [26-28]
As well as providing an epidemiological analysis of the
geographical distribution of South Asians in Scotland, this
allowed us to generate a propensity score for each practice,
representing the expected South Asian proportion given
the other population factors with which it is significantly
correlated. [29]
We compared the prescribing rates for the cases (practices
with South Asian proportions over 5%) with figures for
matched controls and unmatched controls. These figures
are weighted averages where the weights represent the
propensity of each control to match the cases. The pro-
pensity score matching results were estimated using
STATA v8.2. We used the Kernel matching method [30],
though the results are similar with other options. We esti-
mated standard errors via bootstrapping with 100 replica-
tions.
We analysed data for a wide range of drugs used in the
treatment of heart disease, including: statins, beta block-
ers, aspirin, warfarin, ACE inhibitors, clopidogrel, thi-
azide, digoxin, spironolactone and amlodipine.
Prescribing rates were measured by age and sex standardi-
sation of total Gross Ingredient Costs in 2001/2 by Spe-
cific Therapeutic group age-sex weightings related
prescribing units (Star_PUs) for cardiovascular drugs,
with the exception of lipid-lowering drugs for which we
had Defined Daily Doses.
We also obtained a set of GP and practice characteristics
from the General Medical Practitioner Database for Octo-
ber 2002 and GMS payments made to practices in the
2002/3 financial year. The Royal College of General Prac-
titioners (RCGP) supplied lists of practices that had
received Practice Accreditation (PA) or the Quality Prac-
tice Award (QPA) by the end of 2002.
Five variables were used in the matching equation cover-
ing deprivation, health rurality and number of temporary
residents. Deprivation was measured by the Carstairs
score, derived at output level. The Carstairs score is an
unweighted sum of z-scores for four variables representing
car ownership, male unemployment, social class and
overcrowding. For health, two indirectly standardised var-
iables taken from the Census representing the age sex
standardised ratio for limiting long term illness and not
good health were used. Variables representing the propor-
tion of temporary residents and number of patients qual-
ifying for a road mileage payment were also used.
Results
Table 1 lists the variables used for matching and the
matching equation. The table shows that the matching
equation indicates that the cases group is significantly dif-
ferent from practices with less than 1% of the population
with South Asian patients for all the variables with the
exception of the number of temporary residents. Table 1
also shows that the matching process leaves us with a
matched control group of 140 practices. The matched
control group has higher deprivation and morbidity
scores but the differences are not statistically significant.
Both the cases and matched control group have higher
Table 1: Population characteristics and the matching equation
Variable Mean Values Coefficient P-value Mean Value Matched 
Controls (SA<1%)
Difference Between 
Cases And Matched 
Control P value
Mean Value 
Unmatched Controls 
(SA<1%)
All Cases (SA>5%)
Number of Practices 702 39 140 523
Proportion of South 
Asian patients
0.01 0.10 - - 0 <0.001
Carstairs -0.17 2.3 0.45 <0.001 2.6 0.22 -0.7
Census not good 
health
98.9 122 0.11 <0.001 134 0.12 91.4
Census limiting long 
term illness
98.8 107 -0.2 <0.001 121 0.09 95.2
Temporary residents/
practice list size
0.03 0.01 -3.23 0.22 0 0.31 0.05
Proportion of list 
eligible for road 
mileage payments
0.11 0 -2.88 <0.001 0.01 0.15 0.19
Notes: Analysis weighted by list size. Dependent variable in the matching equation is the log-odds of the population proportion in South Asian 
ethnic groups. Adjusted R-squared for the model = 0.59* Figures for matched controls obtained by weighted average using kernel matching.International Journal for Equity in Health 2008, 7:18 http://www.equityhealthj.com/content/7/1/18
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Table 2: Prescribing rates for CHD drugs
Drug Star-PUs
Cases Controls Difference [95% C.I.] % Difference
Unmatched Matched
Statins* (BNF Chapter 2, 2.12) 98.9 99.4 136.7 -37.8 [-66.7 to -11.5] -27.7%
Ace Inhibitors (BNF Chapter 2, 2.5.5) 104.7 97.3 144.4 -39.7 [-64.3 to -14.5] -27.5%
Amlodipine BNF Chapter 2, 2.6) 89.2 107.0 102.2 -13.0 [-44.3 to 13.4] -12.8%
Beta blockers (BNF Chapter 2, 2.4) 92.7 101.9 106.2 -13.5 [-38.9 to 9.9] -12.7%
Clopidogrel (BNF Chapter 2, 2.9) 86.6 99.6 154.3 -67.6 [-105.8 to -17.8] -43.9%
Thiazide ((BNF Chapter 2, 2.5) 92.7 103.4 134.8 -42.2 [-62.7 to -23.6] -31.3%
Aspirin (BNF Chapter 2, 2.9) 109.0 102.2 136.2 -27.2 [-57.7 to 3.6] -20%
Warfarin (BNF Chapter 2, 2.8) 77.2 100.2 101.7 -24.5 [-38.1 to -6.5] -24.1%
Spironolactone (BNF Chapter 2, 2.5) 87.0 100.3 109.8 -22.9 [-63.9 to 0.6] -20.8%
Digoxin (BNF Chapter 2, 2.1) 92.0 100.9 122.6 -30.6 [-55.7 to -9.6] -25%
Notes: * measured in Defined Daily Doses
deprivation and morbidity scores than the unmatched
control group.
For all CHD drugs, case practices have lower prescribing
costs than the matched controls. Significant different are
found for six drugs (statins, ace Inhibitors, clopidogrel,
thiazides, warfarin and digoxin. The differences range
from 12.8% less for amlodipine to 43.9% for clopidogrel.
The case practices also have lower prescribing costs than
the unmatched group with the exception of ace inhibitors
and aspirin. The highest prescribing costs for all drugs are
found in the matched control group. However, this does
not account for differences in deprivation and morbidity
between the matched and unmatched controls group.
Table 3 shows that the cases group has nearly double the
proportion of GPs over 55 than the matched control. Prac-
tices in the case group have significantly fewer GPs per
practice (2.9 to 3.9) and receive less through performing
minor surgery. There are no QPA or PMS practices in the
cases group. The cases group have significantly fewer GPs
(0.57 to 0.66) and WTE GPs (0.58 to 0.73) per 1000 of the
population than the matched controls group. The cases
group also receive significantly lower GMS payments
(47.9 to 53.4)
The unmatched control group has the highest number of
GPs per practice and higher number of GP and WTE per
100 of the population. They are more likely to be a train-
ing, PA or QPA practice. Practices in the unmatched con-
trol group also receive more through minor surgery and
GMS payments than the other two groups.
Discussion
This paper has examined equity of prescribing for a range
of heart disease drugs in Scotland. We have found notable
differences between practices serving areas with more
than 5% of the population in South Asian ethnic groups
and those with similar characteristics, but serving popula-
tions with less than 1%.
Previous research has consistently found that patients
from South Asian ethnic groups have higher levels of
CHD and consequently a greater need for provision and
quality of health care. Thus, the findings of this study
would suggest that prescribing rates and provision of care
in Scotland are inequitable and that the inverse care law
still applies. [10,23]
Possible explanations and implications
Scotland has higher overall rates of CHD than the rest of
the UK and most European countries as evidenced by
available mortality and morbidity statistics. [2,31] South
Asian populations in the UK have a younger age profile
than average leading to lower CHD rates and lower
expected rates of prescribing. [32,33] However, our case
practices are concentrated in one Scottish NHS Board and
this Board has the highest recorded rates of CHD in Scot-
land. [34,35] Moreover the cases group has higher levels
of deprivation than the unmatched control group. Thus
prescribing should be higher in the cases group if depriva-
tion is related to CHD prevalence. But we found higher
prescribing for all drug groups in the unmatched control
group for all but two of the indicators.
The degree to which differences in practice characteristics
can explain our prescribing results is mixed. Case practices
have fewer numbers of GPs who tend to work longerInternational Journal for Equity in Health 2008, 7:18 http://www.equityhealthj.com/content/7/1/18
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Table 3: Practice and GP characteristics
Variable Cases Controls Difference [95% Confidence Interval] Difference %
Unmatched Matched
GP characteristics
Proportion of female GPs 0.37 0.34 0.35 0.02 [-0.06 to 0.12] 5.7%
Average age of GPs 46.2 45.5 44.1 2.1 [-1.6 to 3.5] 4.7%
Proportion of GPs over 55 years 0.19 0.12 0.10 0.09 [0.03 to 0.16] 90%
Practice size
Numbers of GPs per practice 2.9 4.9 3.9 -1.0 [-1.7 to -0.4] -25.7%
Single-handed practice 0.23 0.11 0.11 0.12 [-0.07 to 0.21] 109%
One or two partner practice 0.44 0.35 0.27 0.17 [-0.07 to 0.31] 62.9%
Services offered
Practice does not offer minor surgery 0.18 0.04 0.08 0.10 [-0.04 to 0.19] 125%
Minor surgery payments (£ per capita) 0.67 0.92 0.82 -0.25 [-0.42 to -0.09] -18.3%
Night visit claims per capita 0.03 0.03 0.03 -0.00 [-0.002,0.004] 0.0%
Quality markers
Training practice 0.18 0.25 0.21 -0.03 [-0.2, to 0.01] -14.3%
Practice Accreditation 0.19 0.25 0.24 -0.05 [-0.16 to 0.14] -20.9%
Quality Practice Award 0.00 0.06 0.04 -0.04 [-0.06 to -0.01] 100%
Personal Medical Services 0.00 0.03 0.06 -0.06 [-0.10 to -0.02] 100%
Resources/workload
GPs per 1000 population 0.57 0.88 0.66 -0.09 [-0.14 to,-0.03] -15.7%
WTE GPs per 1000 population 0.58 0.90 0.73 -0.15 [-0.29 to -0.02] -21.6%
Total GMS payments 47.9 57.8 53.4 -4.5 [-6.1 to -2.2] -10.3
hours than those in the matched control group. This is of
concern since South Asian patients have higher than aver-
age consultation rates. [36] Consequently a greater work-
load is placed on a fewer number of doctors within the
cases group and lower prescribing rates have been found
to be positively associated with lower ratios of GPs to
patients. [37] Moreover, research into aspects of quality of
care have emphasised the importance of adequate time
for consultations with the view that GPs require greater
time to be allowed to treat complex diseases such as CHD
in the proper manner. [36,38] There is little evidence with
regard to the impact on prescribing rates for practices with
accreditation. However, there is some evidence that train-
ing practices, of which there are far fewer in the cases
group, have lower prescribing rates than non-training
practices. [39,40]
Strengths and weaknesses of the study
This study has the advantage of 100% coverage since the
data are available for all practices. At the time the study
was conducted other than for statins only cost data was
available to the authors. Previous research has suggested
that using prescribing rates based on prevalence rates is
more beneficial than derived from costs patterns. [41]
However volume remains the main driver of prescribing
costs and needs based formulas adopted in England for
prescribing expenditures have been based on net ingredi-
ent cost. [38]. This study has the advantage of 100% cov-
erage since the data are available for all practices. The
findings are consistent across a wide range of drugs used
in the treatment of heart disease. Lower levels of prescrib-
ing are observed relative to all other practices and to a set
of matched controls. However, the analysis is ecological
and the magnitude of the differences suggests that the
results cannot be explained wholly by relative under-pre-
scribing to South Asian individuals but rather is indicativeInternational Journal for Equity in Health 2008, 7:18 http://www.equityhealthj.com/content/7/1/18
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of prescribing of practices in more deprived areas. We
have estimated more than 20% differences in prescribing
rates, yet South Asians represent only 9% of the popula-
tion in the cases group. Taking account of the higher prev-
alence rate in South Asians suggests that no more than
11% of heart disease patients are South Asian. Even if no
South Asian patients receive treatment and all non-South
Asian patients receive treatment, this cannot account for
the 20% difference in prescribing. Our results must there-
fore reflect, at least in part, contextual influences rather
than compositional characteristics alone. [37] Our compar-
ison of structural factors suggests that there are considera-
ble differences in the structure of care delivery that may
constitute part of these contextual influences.
Conclusion
This study shows that South Asians tend to be registered
with practices with lower prescribing rates, but it would
appear that all patients in these practices are at greater risk
of having lower prescribing rates. Moreover, patients in
these practices also suffer from poorer access to and lower
quality GP services. Understanding the structural, attitudi-
nal or behavioural reasons for lower prescribing in these
practices and how these are affected by GP and practice
provision is a challenge for future work. Identifying
whether South Asian individuals are less likely to receive
heart disease drugs than non South Asians will require
individual-level prescribing analysis. Our results suggest
that it will be important to identify the role of practice-
related factors.
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